- Home
- MIY vs ANNX Comparison
MIY vs ANNX Comparison
Compare MIY & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIY
- ANNX
- Stock Information
- Founded
- MIY 1992
- ANNX 2011
- Country
- MIY United States
- ANNX United States
- Employees
- MIY N/A
- ANNX N/A
- Industry
- MIY Investment Bankers/Brokers/Service
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- MIY Finance
- ANNX Health Care
- Exchange
- MIY Nasdaq
- ANNX Nasdaq
- Market Cap
- MIY 340.0M
- ANNX 362.4M
- IPO Year
- MIY N/A
- ANNX 2020
- Fundamental
- Price
- MIY $11.62
- ANNX $2.81
- Analyst Decision
- MIY
- ANNX Strong Buy
- Analyst Count
- MIY 0
- ANNX 7
- Target Price
- MIY N/A
- ANNX $15.80
- AVG Volume (30 Days)
- MIY 56.8K
- ANNX 1.3M
- Earning Date
- MIY 01-01-0001
- ANNX 03-25-2025
- Dividend Yield
- MIY 3.98%
- ANNX N/A
- EPS Growth
- MIY N/A
- ANNX N/A
- EPS
- MIY N/A
- ANNX N/A
- Revenue
- MIY N/A
- ANNX N/A
- Revenue This Year
- MIY N/A
- ANNX N/A
- Revenue Next Year
- MIY N/A
- ANNX N/A
- P/E Ratio
- MIY N/A
- ANNX N/A
- Revenue Growth
- MIY N/A
- ANNX N/A
- 52 Week Low
- MIY $9.45
- ANNX $2.64
- 52 Week High
- MIY $11.70
- ANNX $8.40
- Technical
- Relative Strength Index (RSI)
- MIY 56.67
- ANNX 26.19
- Support Level
- MIY $11.44
- ANNX $2.64
- Resistance Level
- MIY $11.58
- ANNX $3.24
- Average True Range (ATR)
- MIY 0.11
- ANNX 0.23
- MACD
- MIY 0.00
- ANNX -0.02
- Stochastic Oscillator
- MIY 66.67
- ANNX 14.77
About MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from federal and Michigan income taxes.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.